Retraction of: Scientific Reports https://doi.org/10.1038/s41598-022-24151-3, published online 14 November 2022
The Editors have retracted this Article. After publication, concerns were raised regarding irregularities in the flow cytometry plots presented in Fig. 7. The Authors have explained these irregularities, but have been unable to share the underlying raw data upon request.
Further checks by the Publisher found further potential irregularities in the data presented in Figs. 10 and 11. The Authors have stated that this and other cell line experiments in the study (Figs. 5–11) were performed by a third party, and the raw data are not available.
The Editors therefore no longer have confidence in the presented data.
The Publisher has not been able to obtain current email addresses for Mohamed A. Alfaleh and Usama A. Fahmy. None of the other Authors have responded to any correspondence from the Publisher about this retraction.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Alfaleh, M.A., Fahmy, O., Al-Rabia, M.W. et al. Retraction Note: Hybrid nanoparticulate system of Fluvastatin loaded phospholipid, alpha lipoic acid and melittin for the management of colon cancer. Sci Rep 14, 27831 (2024). https://doi.org/10.1038/s41598-024-78897-z
Published:
Version of record:
DOI: https://doi.org/10.1038/s41598-024-78897-z
